Rapport Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Rapport Therapeutics, Inc. (RAPP) had Debt Securities, Available-for-sale, Amortized Cost of $373.74 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $373.74M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $399.23M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $437.35M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $261.52M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $373.74M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $399.23M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $437.35M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $261.52M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $205.46M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $227.87M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $249.00M 10-K · filed 2026-03-10 |
| 2024-09-30 | $280.95M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $226.16M 10-Q · filed 2024-08-08 |
| 2023-12-31 | $77.31M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |